29 completed, 6 terminated, 4 withdrawn, 3 unknown. 46 Phase 1, 6 Phase 2.
Follow Advanced Cancers: new trials by email Literature Review of Advanced Cancers trials Research Report on Advanced Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers TQB2922 injection (subcutaneous injection) - Advanced Cancers | Phase 1 | Recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 42 | 2025-12-16 | 2026-09-10 |
| A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors TQB2252 injection - Advanced Cancers | Phase 1 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | 100 | 2024-11-01 | 2024-10-21 |
| A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors TQB3107 Tablets - Advanced Cancers | Phase 1 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 140 | 2024-06-27 | 2026-07-29 |
| Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers TQB3602 Capsule + AK105 Injection - Advanced Cancers | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 7 | 2022-07-29 | 2023-07-27 |
| Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers TQB2930 injection - Advanced Cancers | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 60 | 2022-05-01 | 2022-05-19 |
| Hepatic Impairment Study for Lorlatinib in Cancer Patients lorlatinib - Advanced Cancers | Phase 1 | Terminated | Pfizer | 1 | 2020-01-14 | 2024-06-21 |
| Plasmodium Immunotherapy for Advanced Cancers Blood-stage infection of P.vivax - Advanced Cancers | Phase 1 / Phase 2 | Unknown | CAS Lamvac Biotech Co., Ltd. | 20 | 2017-11-23 | 2024-02-20 |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies MGN1703, Ipilimumab - Advanced Cancers, Melanoma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 28 | 2016-05-11 | 2026-04-07 |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies DCC-2618 - Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 282 | 2015-11-01 | 2023-12-13 |
| A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Co-ArgI-PEG - Advanced Cancers | Phase 1 | Completed | Immedica Pharma AB | 76 | 2015-10-22 | 2026-08-06 |
| A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy [18F] Fluciclatide, PET/CT Scan, Phone Calls - Advanced Cancers | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2014-08-01 | 2014-07-18 | |
| MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies MLN9708, Vorinostat - Advanced Cancers | Phase 1 | Completed | M.D. Anderson Cancer Center | 68 | 2014-06-27 | 2022-07-11 |
| Regorafenib and Cetuximab in Patients With Advanced Malignancy Regorafenib, Cetuximab, Questionnaire - Advanced Cancers | Phase 1 | Completed | M.D. Anderson Cancer Center | 39 | 2014-03-19 | 2021-04-01 |
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Azacitidine, Vorinostat, Gemcitabine - Advanced Cancers, Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 61 | 2013-11-07 | 2020-01-27 |
| CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL) Leukapheresis, Fludarabine, Cyclophosphamide - Advanced Cancers, Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 30 | 2013-06-11 | 2017-08-17 |
| Dasatinib and Crizotinib in Advanced Cancer Crizotinib, Dasatinib - Advanced Cancers | Phase 1 | Completed | M.D. Anderson Cancer Center | 62 | 2013-03-01 | 2023-06-07 |
| Ipilimumab and Lenalidomide in Advanced Cancer Ipilimumab, Lenalidomide - Advanced Cancers | Phase 1 | Completed | M.D. Anderson Cancer Center | 101 | 2013-03-01 | 2019-02-25 |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib SIR-Spheres, Cetuximab, Erlotinib - Advanced Cancers | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2012-12-01 | 2013-04-09 | |
| Study of Curcumin, Vorinostat, and Sorafenib Curcumin, Sorafenib, Vorinostat - Advanced Cancers | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2012-11-01 | 2012-10-19 | |
| Study of Vemurafenib, Carboplatin, and Paclitaxel Vemurafenib, Carboplatin, Paclitaxel - Advanced Cancers | Phase 1 | Completed | M.D. Anderson Cancer Center | 21 | 2012-07-09 | 2020-06-18 |
Showing 20 of 46. Sign in to see all of them.
Neoplasm Metastasis (8) · Lymphoma (4) · Neoplasms (4) · Melanoma (3) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Dyspnea (1) · Gastrointestinal Stromal Tumors (1) · Glioblastoma (1) · Glioma (1) · Hematologic Neoplasms (1) · Leukemia (1)
Neoplasms (15) · Pathological Conditions, Signs and Symptoms (10) · Pathologic Processes (9) · Neoplasms by Histologic Type (8) · Neoplastic Processes (8) · Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (6) · Lymphoproliferative Disorders (6) · Lymphatic Diseases (5) · Neoplasms by Site (5) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Hematologic Diseases (3) · Neoplasms, Nerve Tissue (3)
Bevacizumab (4) · Cetuximab (4) · Erlotinib Hydrochloride (4) · Vorinostat (4) · Albumin-Bound Paclitaxel (3) · Azacitidine (3) · Lenalidomide (3) · Oxaliplatin (3) · Surveys and Questionnaires (3) · pazopanib (3) · temsirolimus (3) · 130-nm albumin-bound paclitaxel (2) · Carboplatin (2) · Crizotinib (2) · Fluorouracil (2)
M.D. Anderson Cancer Center (34) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · CAS Lamvac Biotech Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · Deciphera Pharmaceuticals, LLC (1) · Immedica Pharma AB (1) · Ionis Pharmaceuticals, Inc. (1) · Janssen Research & Development, LLC (1) · Pfizer (1) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (1) · Yale University (1)
United States (36) · China (6) · Canada (1) · Germany (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
David S. Hong, MD (5) · Filip Janku, MD, PHD (4) · Apostolia M. Tsimberidou, MD, PHD (3) · Siqing Fu, MD, PHD (3) · Aung Naing, MD (2) · Jennifer J. Wheler, MD (2) · Apostolia M. Tsimberidou, MD, PhD (1) · Apostolia M. Tsimberidou, MD,PHD (1) · Chitra M. Hosing, MD (1) · Daniel Karp, MD (1) · David Hong, MD (1) · David Hui, MD (1) · David S Hong, MD (1) · Hari Deshpande, M.D. (1)
PMID 21931708, PMID 22491798, PMID 23756764, PMID 23830530, PMID 24668327, PMID 24746841, PMID 26062823, PMID 26698868, PMID 28228842, PMID 28422758, PMID 28445973, PMID 28650446, PMID 28874596, PMID 30446007, PMID 32804590, PMID 39787747, PMID 39959251